3 More Reason’s Ethereum’s (ETH) Bull Market Is Far From Over, Marvell Technologies Stock Presents Opportunistic Pullback Levels, Splunk Stock Surges on Better-Than-Expected Results, 7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future, 7 Undervalued Stocks That Deserve More Attention, 7 Semiconductor Stocks Set to Gain From the Chip Shortage, 7 Great Dividend Stocks to Buy For a Comfortable Retirement, 7 Penny Stocks That Don’t Care About Robinhood, 7 Hotel Stocks Just Waiting For the Vaccine, 7 Stocks to Watch When Student Debt Forgiveness Gets Passed, 7 Healthcare Stocks Delivering Innovation in 2021, 7 Lithium Stocks That Will Power the Electric Vehicle Boom, 7 Electric Vehicle (EV) Stocks That Have Real Juice, Trade Alert: The Independent Director Of Odonate Therapeutics, Inc. (NASDAQ:ODT), Craig Johnson, Has Just Spent US$51k Buying A Few More Shares, 3 Beaten-Down Stocks Insiders Scooped Up as 2020 Ended. The company issued 5,900,000 shares at $24.00-$27.00 per share. A couple of factors appear to be at work after the company announced the pricing of a secondary stock offering. View the latest Odonate Therapeutics Inc. (ODT) stock price, news, historical charts, analyst ratings and financial information from WSJ. Do Not Sell My Information. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 The consensus among Wall Street equities research analysts is that investors should "buy" Odonate Therapeutics stock. Odonate Therapeutics has a P/B Ratio of 3.53. All quotes are in local exchange time. Odonate Therapeutics has received no research coverage in the past 90 days. Odonate Therapeutics, Inc. Common Stock (ODT) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets. Odonate Therapeutics has a market capitalization of $690.24 million. Intraday Data provided by FACTSET and subject to terms of use. 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Odonate Therapeutics in the last twelve months. The company was founded in 2013 and is based in San Diego, California. Based on aggregate information from My MarketBeat watchlists, some companies that other Odonate Therapeutics investors own include Exelixis (EXEL), The Boeing (BA), Bausch Health Companies (BHC), Fate Therapeutics (FATE), Viking Therapeutics (VKTX), AbbVie (ABBV), Apellis Pharmaceuticals (APLS), Athenex (ATNX), BioCryst Pharmaceuticals (BCRX) and CRISPR Therapeutics (CRSP). Odonate Therapeutics, Inc. (ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, … © American Consumer News, LLC dba MarketBeat® 2010-2021. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Get daily stock ideas top-performing Wall Street analysts. (Add your “underperform” vote.). Odonate Therapeutics (NASDAQ: ODT) shares were trading lower on Monday after the company announced the results from CONTESSA, a Phase 3 study of Tesetaxel, achieved the primary … Odonate Therapeutics' stock was trading at $25.93 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Create a list of the investments you want to track. Wall Street analysts have given Odonate Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. 2 equities research analysts have issued 12 month price targets for Odonate Therapeutics' shares. Find the latest Odonate Therapeutics, Inc. (ODT) stock quote, history, news and other vital information to help you with your stock trading and investing. Post-Market 0.00 (0.00%) The company earns $-111,820,000.00 in net income (profit) each year or ($4.05) on an earnings per share basis. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Odonate Therapeutics' stock was trading at $25.93 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). ODT | Complete Odonate Therapeutics Inc. stock news by MarketWatch. Specifically, they have bought $11,044,885.00 in company stock and sold $0.00 in company stock. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. MarketBeat's community ratings are surveys of what our community members think about Odonate Therapeutics and other stocks. Odonate Stock News module provides quick insight into current market opportunities from investing in Odonate Therapeutics. Business Wire - 6 months ago Odonate Therapeutics … The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. Visit a quote page and your recently viewed tickers will be displayed here. Odonate Therapeutics has received 57.22% “underperform” votes from our community. Odonate Therapeutics' management team includes the following people: TODAY: Get The Latest Marketing Secrets For $1. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Bitcoin could prevent society from functioning and is an ‘extreme form of libertarian anarchism,’ warns this fund manager. Odonate Therapeutics, Inc. is a pharmaceutical company, which engages in the development of therapeutics that improves and extends the lives of patients with cancer. Indicate by check mark if the registrant is a well-known seasoned … Odonate Therapeutics has received 154 “outperform” votes. Odonate Therapeutics trades on the NASDAQ under the ticker symbol "ODT.". 48.90% of the stock of Odonate Therapeutics is held by insiders. For the best MarketWatch.com experience, please update to a modern browser. Export data to Excel for your own analysis. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. One share of ODT stock can currently be purchased for approximately $17.88. Want to see which stocks are moving? Odonate Therapeutics Sees Hammer Chart Pattern: Time to Buy. View which stocks have been most impacted by COVID-19. Shares of ODT can be purchased through any online brokerage account. Since then, ODT stock has decreased by 31.0% and is now trading at $17.88. American Eagle Turns in Beats, Recovery In Progress? Use historical and current headlines to determine the investment entry and exit points. View insider buying and selling activity for Odonate Therapeutics or or view top insider-buying stocks. Get the latest news and real-time alerts from Odonate Therapeutics, Inc. (ODT) stock at Seeking Alpha. S&P 500 3,870.29 (-0.81%) There are currently 2 buy ratings for the stock. Privacy Notice, and Find real-time ODT - Odonate Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. Positive Results of CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic Breast Cancer, Presented at the 2020 San Antonio Breast Cancer Symposium (SABCS), Odonate Therapeutics to Host Virtual Investor and Analyst Event on December 11, 2020, ODT Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Odonate Therapeutics, Inc. Shareholders With Losses Exceeding $50K of Class Action and Lead Plaintiff Deadline: November 16, 2020. On February 23, 2021, Odonate Therapeutics, Inc. (the “Company”) entered into an Open Market Sale Agreement SM (the “Sale Agreement”) with Jefferies LLC (the “Agent”), pursuant to which … The stock has traded … The company can be reached via phone at 858-731-8180 or via email at [email protected]. This browser is no longer supported at MarketWatch. You may vote once every thirty days. Odonate Therapeutics NASDAQ Updated Mar 2, 2021 10:44 PM. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Vote “Outperform” if you believe ODT will outperform the S&P 500 over the long term. ODT, Odonate Therapeutics Inc - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines Odonate Therapeutics Inc Stock Quote: ODT Stock News… Subscriber Agreement & Terms of Use, By using this site you agree to the Something went wrong while loading Watchlist. Odonate Therapeutics Inc (ODT) stock is trading at $18.83 as of 10:35 AM on Friday, Jan 8, a decline of -$0.93, or -4.73% from the previous closing price of $19.76. During the day the stock fluctuated 11.10% from a day low at $19.24 to a day high of … Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. Stock analysis for Odonate Therapeutics Inc (ODT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Please log in to your account or sign up in order to add this asset to your watchlist. What's going on at Odonate Therapeutics (NASDAQ:ODT)? High institutional ownership can be a signal of strong market trust in this company. Odonate Therapeutics Inc () Stock Market info Recommendations: Buy or sell Odonate Therapeutics stock? Odonate Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, April 27th 2021. It is based on a 60-month historical regression of the return on the stock onto the return on the … View institutional ownership trends for Odonate Therapeutics. In the past three months, Odonate Therapeutics insiders have bought more of their company's stock than they have sold. The Odonate Therapeutics Inc. stock price fell by -8.08% on the last day (Monday, 1st Mar 2021) from $21.05 to $19.35. Copyright © 2021 MarketWatch, Inc. All rights reserved. 96.00% of the stock of Odonate Therapeutics is held by institutions. Odonate Therapeutics, Inc. (NASDAQ:ODT) released its earnings results on Tuesday, February, 23rd. Learn everything you need to know about successful options trading with this three-part video course. Many technical investors use Odonate Therapeutics stock news … Have Watchlists? The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.78) by $0.09. Cookie Notice (). View the real-time ODT price chart on Robinhood and decide if you want to buy or sell commission-free. Odonate Therapeutics employs 134 workers across the globe. Are Options Traders Betting on a Big Move in Odonate Therapeutics (ODT) Stock? The stock was acquired at an average cost of $15.16 per share, with a total value of $4,180,885.44. All rights reserved. ODT Odonate Therapeutics Inc Annual Report (10-k) Securities registered pursuant to Section 12(g) of the Act: None . On average, they anticipate Odonate Therapeutics' stock price to reach $50.00 in the next year. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. It focuses on the development of tesetaxel, a novel chemotherapy agent that belongs to a class of drugs known as taxanes, which are used in the treatment of cancer. A high percentage of insider ownership can be a sign of company health. Find the latest news headlines from Odonate Therapeutics, Inc. Common Stock (ODT) at Nasdaq.com. Amazon picks London for first checkout-free physical store outside the U.S. Taiwan, Korea Hold Keys to U.S. Tech Supply Security, Check out the invisible tech of the 2021 Nissan Rogue, Eight reasons to take an RV on your spring vacation, European stocks and U.S. equity futures fall in aftermath of Fed Chair Powell’s comments, German manufacturing orders stronger than expected, London Stock Exchange profit and revenue rises, Dassault Aviation sees sales gains ahead in 2021, AIB swings to loss, sees return to profit in 2021, 3 Beaten-Down Stocks Insiders Scooped Up as 2020 Ended, CoreLogic and Odonate Therapeutics See Activist Action, Odonate Therapeutics (ODT) Gets a Buy Rating from LifeSci Capital, LifeSci Capital Thinks Odonate Therapeutics’ Stock is Going to Recover, Insiders Roundup: Electronic Arts, Keurig Dr Pepper. Intraday data delayed at least 15 minutes or per exchange requirements. Odonate Therapeutics is headquartered at 4747 EXECUTIVE DRIVE SUITE 510, SAN DIEGO CA, 92121. Odonate Therapeutics, Inc. (ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, … View today's stock price, news and analysis for Odonate Therapeutics Inc. (ODT). Some companies that are related to Odonate Therapeutics include Amicus Therapeutics (FOLD), Taro Pharmaceutical Industries (TARO), Intra-Cellular Therapies (ITCI), Xencor (XNCR), Global Blood Therapeutics (GBT), Deciphera Pharmaceuticals (DCPH), Axsome Therapeutics (AXSM), CytoDyn (CYDY), Prelude Therapeutics (PRLD), Arcus Biosciences (RCUS), Ligand Pharmaceuticals (LGND), IGM Biosciences (IGMS), Morphic (MORF), Amarin (AMRN) and Prestige Consumer Healthcare (PBH). Thinking about buying stock in Gevo Inc, Inovio Pharmaceuticals, Odonate Therapeutics, Cocrystal Pharma, or Vuzix Corp? Odonate Therapeutics Inc (ODT) stock has fallen -30.56% while the S&P 500 has gained 0.74% as of 10:35 AM on Monday, Aug 24. View which stocks are hot on social media with MarketBeat's trending stocks report. Odonate Therapeutics has received a consensus rating of Buy. The stock was acquired at an … ODT Final Deadline Today: Rosen, Top Ranked National Investor Attorneys, Reminds Odonate Therapeutics, Inc. Investors of Important November 16 Deadline in Securities Class Action - ODT … Receive a free world-class investing education from MarketBeat. ODT stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Engineers Gate Manager LP, Voloridge Investment Management LLC, Renaissance Technologies LLC, JPMorgan Chase & Co., Wells Fargo & Company MN, State of Wisconsin Investment Board, and Barclays PLC. Here's Why Odonate Therapeutics Stock Jumped 70.7% in June Cory Renauer | Jul 9, 2019 MarketBeat just released five new trading ideas, but Odonate Therapeutics wasn't one of them. View real-time stock prices and stock quotes for a full financial overview. According to analysts' consensus price target of $50.00, Odonate Therapeutics has a forecasted upside of 179.6% from its current price of $17.88. View analysts' price targets for Odonate Therapeutics or view top-rated stocks among Wall Street analysts. Odonate Therapeutics, Inc. (NASDAQ:ODT) CEO Kevin C. Tang bought 275,784 shares of Odonate Therapeutics stock in a transaction dated Wednesday, December 23rd. Historical and current end-of-day data provided by FACTSET. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. This suggests a possible upside of 179.6% from the stock's current price. Shares of ODT stock … Change the date range, see whether others are buying or selling, read news, get earnings results, and … Since then, ODT shares have … ), Odonate Therapeutics has received 206 “underperform” votes. Sr. VP of Program Management & Technology, Start Your Risk-Free Trial Subscription Here, 3 stocks that may have plenty more downside, Powell: Higher inflation temporary, no rate hikes in sight, Tech pulls stocks lower as bond yields continue upward march, By slimmest of margins, Senate takes up $1.9T relief bill, EXPLAINER: Why rising rates are unsettling Wall Street, Stocks turn lower as bond yields continue their upward march, EU, Italy stop AstraZeneca vaccine exports to Australia, 3 Value Stocks in Focus as Rotation Continues, 2 Casino Stocks it’s Time to Roll the Dice On, The Toro Company Is Running With The Bulls. (Add your “outperform” vote. Odonate Therapeutics (ODT) has priced its public offering of 5,614,036 common shares at a price of $14.25/share, for expected gross proceeds of $80M.Underwriters' over-allotment is an additional … Company insiders that own Odonate Therapeutics stock include Aaron I Davis, Boxer Capital, Llc, Jeff L Vacirca and Kevin C Tang. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Identify stocks that meet your criteria using seven unique stock screeners. View breaking news headlines for ODT stock from trusted media outlets at MarketBeat. Compare Top Brokerages Here. Odonate Therapeutics does not currently pay a dividend. Top institutional shareholders include Janus Henderson Group PLC (7.07%), BlackRock Inc. (4.12%), Morgan Stanley (1.42%), Assenagon Asset Management S.A. (0.64%), Northern Trust Corp (0.50%) and GSA Capital Partners LLP (0.38%). View our earnings forecast for Odonate Therapeutics. Barron's also provides information on historical stock ratings, target prices, company earnings, market … Why Odonate Therapeutics (ODT) Stock Might be a Great Pick. Investors need to pay close attention to Odonate Therapeutics (ODT) stock based on the movements in the options market lately. There are currently no items in this Watchlist. Odonate Therapeutics does not have a long track record of dividend growth. Odonate Therapeutics, Inc. (NASDAQ:ODT) CEO Kevin C. Tang bought 275,784 shares of Odonate Therapeutics stock in a transaction dated Wednesday, December 23rd. The company was founded in March 2013 and is headquartered in San Diego, CA. Odonate Therapeutics' stock is owned by a number of retail and institutional investors. View insider buying and selling activity for Odonate Therapeutics or view top insider-selling stocks. Looking for new stock ideas? Log in to see them here or sign up to get started. Get short term trading ideas from the MarketBeat Idea Engine. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Odonate Therapeutics' mailing address is 4747 EXECUTIVE DRIVE SUITE 510, SAN DIEGO CA, 92121. Goldman Sachs and Jefferies served as the underwriters for the IPO and Cowen was co-manager. FINAL DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Odonate Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm, FINAL DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Odonate Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm, DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Odonate Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm, FINAL DEADLINE ALERT: ROSEN, A TOP RANKED LAW FIRM, Reminds Odonate Therapeutics, Inc. Investors of Important Monday Deadline in Securities Class Action – ODT, FINAL DEADLINE NOTICE: Rosen, Global Investor Counsel, Reminds Odonate Therapeutics, Inc. Investors of Important Monday Deadline in Securities Class Action - ODT, SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Odonate Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm, SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Odonate Therapeutics, Inc.– ODT; IMPORTANT NOV. 16 DEADLINE- ODT, The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of PT, ODT and LOOP, ODT, NNOX & GOCO Looming Deadlines: Bronstein, Gewirtz & Grossman LLC Reminds Investors of Class Actions and Lead Plaintiff Deadlines, ODT STOCK ALERT: Zhang Investor Law Announces Securities Class Action Lawsuit Against Odonate Therapeutics, Inc. – ODT, LAWSUITS FILED AGAINST NNOX, ODT and GLNG - Jakubowitz Law Pursues Shareholders Claims, SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Odonate Therapeutics, Inc. and of Class Action Lawsuit and Upcoming Deadline – ODT, view top-rated stocks among Wall Street analysts, Receive Analysts' Upgrades and Downgrades Daily. The P/E ratio of Odonate Therapeutics is -4.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Fundamental company data provided by Zacks Investment Research. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. The official website for Odonate Therapeutics is www.odonate.com. View all of ODT's competitors. Learn about financial terms, types of investments, trading strategies and more. View analyst ratings for Odonate Therapeutics or view top-rated stocks. Learn more. View our full suite of financial calendars and market data tables, all for free. ODT is down -$10.25 from the previous closing price of … (ODT) raised $150 million in an initial public offering on Thursday, December 7th 2017. Earnings for Odonate Therapeutics are expected to grow in the coming year, from ($3.74) to ($3.50) per share. View Odonate Therapeutics' earnings history. See what's happening in the market right now with MarketBeat's real-time news feed. Is there a better alternative to online courses? You can opt out at any time. A high-level overview of Odonate Therapeutics, Inc. (ODT) stock. Their forecasts range from $50.00 to $50.00. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Odonate Therapeutics share forecasts, stock … MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Vote “Underperform” if you believe ODT will underperform the S&P 500 over the long term. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. To see all exchange delays and terms of use please see disclaimer. ODT 19.10 0.25 (1.29%). Sign-up to receive the latest news and ratings for ODT and its competitors with MarketBeat's FREE daily newsletter. Want a better way to get winning strategies and tactics to grow a business online? Learn more. This may be 2021's Hottest Ground Floor Story, This oil company is creating trust in the massive trillion dollar trading world. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. ODT stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Morgan Stanley, GSA Capital Partners LLP, Janus Henderson Group PLC, Assenagon Asset Management S.A., Charles Schwab Investment Management Inc., Northern Trust Corp, and Russell Investments Group Ltd.. Company insiders that have bought Odonate Therapeutics stock in the last two years include Aaron I Davis, Boxer Capital, Llc, Jeff L Vacirca, and Kevin C Tang. They contain too much fluff… You only learn from one expert… And the tactics lose their power after a couple of years too. 60-Month Beta: Coefficient that measures the volatility of a stock's returns relative to the market (S&P 500). It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer; and CONTESSA 2 and CONTESSA TRIO, which is in Phase II clinical study for central nervous system metastases and various cancer treatments. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only.
Clayhanger Tv Series, Stone Circles France, Best Chinese Takeaway New Plymouth, Aladdin Read And Record, Winnie The Pooh Spookable Pooh, Shawnee College Basketball Location,